Biotech firm Mabpharm tests Hong Kong listing
China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: